AMPH250117P30000
- 0.00
- 0.000.00%
Amphastar Pharmaceuticals Newsroom
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Express News | Amphastar Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $46 From $55
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Little Excitement Around Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Earnings
Amphastar Pharmaceuticals Insiders Sold US$975k Of Shares Suggesting Hesitancy
Amphastar Pharma Analyst Ratings
Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Announces Target Price $55
US Manufacturing Index Rises To 43, Highest Since 2020
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Amphastar Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Amphastar Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results.
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $66
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript Summary
Amphastar Pharmaceuticals Non-GAAP EPS of $0.96 Misses by $0.02, Revenue of $191.2M Misses by $3.49M
Amphastar Pharmaceuticals Expands Share Buyback Program By $50M To Offset Equity Compensation Dilution, With No Set End Date
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q3 EPS $0.96
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q3 Revenue $191.2M